Axim Biotechnologies Inc   (AXIM)
Other Ticker:  
Price: $0.0165 $0.00 -9.341%
Day's High: $0.0179 Week Perf: 1.85 %
Day's Low: $ 0.02 30 Day Perf: -14.51 %
Volume (M): 1,015 52 Wk High: $ 0.06
Volume (M$): $ 17 52 Wk Avg: $0.02
Open: $0.02 52 Wk Low: $0.01

 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 479
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Axim Biotechnologies Inc
Axim Biotechnologies Inc is a biotechnology company that specializes in the development of pharmaceutical and nutraceutical products. The company focuses on utilizing cannabinoid compounds for various medicinal purposes. Axim Biotechnologies conducts research, development, and clinical trials to create innovative therapies and treatments for conditions such as multiple sclerosis, irritable bowel syndrome, psoriasis, and opioid addiction. The company's goal is to provide safe and effective solutions for patients through the use of cannabinoids.

   Company Address: 6191 Cornerstone Court San Diego 92121 CA
   Company Phone Number: 923-4422   Stock Exchange / Ticker: AXIM
   AXIM is expected to report next financial results on April 16, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Scaling Up Diagnostic Tools: AXIM Biotechnologies Joins Hands with Auer Precision to Amplify Assay Production

Published Wed, Dec 20 2023 2:00 PM UTC

Biotech company AXIM Biotechnologies has entered into a critical partnership with a leading diagnostic manufacturer, Auer Precision, to scale up the production of diagnostic assays for testing Immunoglobulin E (IgE) and Lactoferrin DED, marking a significant milestone in the evolution of the diagnostic healthcare industry.AXIM Biotechnologies, fervently dedicated to amplifyi...

Axim Biotechnologies Inc

Axim Biotechnologies Inc Shatters Expectations with Record-Breaking Numbers for Fiscal Q3 2023

Axim Biotechnologies Inc, a leading player in the biotech industry, has showcased impressive performance in the fiscal third quarter of 2023. While many businesses in the Major Pharmaceutical Preparations sector have struggled with dwindling revenues and diminishing top-line, Axim Biotechnologies Inc has managed to achieve a remarkable turnaround.
The company reported balanced books in the fiscal third quarter of 2023, with earnings per share reaching $0.00. This is a significant improvement compared to the previous year's figure of $-0.01 per share and indicates a positive trend for the company. Additionally, the company demonstrated growth in terms of revenue, with a sharp increase to $0.01 million from $0.00 million in the corresponding reporting season a year before.

Axim Biotechnologies Inc

Axim Biotechnologies Inc Surprises Market with Revenue of $0.009929 Million, but Faces Mounting Net Shortfall of $-3.723 Million

Axim Biotechnologies Inc is a biotechnology company that recently reported a revenue of $0.009929 million in the second quarter of 2023. Despite this positive revenue, the company experienced a net shortfall of $-3.723 million, which is higher compared to $-1.223 million in the same period last year.
This significant increase in net shortfall is a concerning factor for Axim Biotechnologies Inc. However, it is important to note that financial results can fluctuate throughout the year, and it is possible that the company can make improvements in the future. Investors will need to keep a close eye on the company's financial performance to assess if these shortfalls continue or if the company can recover in upcoming quarters.

Axim Biotechnologies Inc

AXIM Biotechnologies Reports Remarkable Revenue Uptick in Q1 Report of 2023

Axim Biotechnologies Inc, a leading biotech company, has recently announced its revenue results for the financial year closing on March 31, 2023. According to the report, the company's revenue for this period has been $0.007397 million. While this figure may seem small, it is a positive sign that the company is generating revenue even in a challenging economic environment.
However, the financial results for Axim Biotechnologies Inc are not entirely positive. The net shortfall for the company for this financial year was $-2.763 million, which is significantly higher than the previous year's net shortfall of $-2.087 million. This is a cause for concern, as a growing net shortfall generally implies that the company's expenses are increasing, while its revenue is decreasing.


Axim Biotechnologies Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com